Oruka Therapeutics

Yahoo Finance • 6 hours ago

MoonLake rebounds despite downgrades prompted by trial setback

[Sign for Wall Street in New York City] Pharrel Wiliams MoonLake Immunotherapeutics (NASDAQ:MLTX [https://seekingalpha.com/symbol/MLTX]) traded higher on Tuesday even as Wall Street opted to downgrade the Swiss biotech following a late-st... Full story

Yahoo Finance • 13 days ago

Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker

Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis. Continue Reading View Comments... Full story

Yahoo Finance • 13 days ago

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

[Clinical Drug Trials with inspiration and healthcare/medical concept on desk background] syahrir maulana/iStock via Getty Images Oruka Therapeutics (NASDAQ:ORKA [https://seekingalpha.com/symbol/ORKA]) added ~20% in the premarket on Wedne... Full story

Yahoo Finance • 14 days ago

Oruka Therapeutics Reports Positive Interim Data From Phase 1 Study Of ORKA-001

(RTTNews) - Oruka Therapeutics, Inc. (ORKA) Tuesday announced positive interim data from its Phase 1 study evaluating the safety and pharmacokinetics of ORKA-001 in healthy volunteers. ORKA-001, a long-acting monoclonal antibody targeting... Full story

Yahoo Finance • 14 days ago

Oruka Therapeutics Announces $180 Million Private Placement

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic ski... Full story

Yahoo Finance • 14 days ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated wi... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presen... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics stock rises after FDA clears IND for psoriasis drug

Investing.com -- Oruka Therapeutics Inc (NASDAQ:ORKA) stock rose 6.6% after the company announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for a Phase 2a trial of ORKA-001... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral presentation at EADV... Full story

Yahoo Finance • 3 months ago

Oruka Therapeutics announces COO appointment

* Oruka Therapeutics (NASDAQ:ORKA [https://seekingalpha.com/symbol/ORKA]) has promoted Laura Sandler to chief operating officer. * Sandler joined Oruka in 2024 as SVP of Operations and has over 20 years of experience in biopharma leade... Full story

Yahoo Finance • 3 months ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin d... Full story

Yahoo Finance • 4 months ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin di... Full story

Yahoo Finance • 4 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a... Full story

Yahoo Finance • 7 months ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar binding affinity an... Full story

Yahoo Finance • 7 months ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple opportunities to show differ... Full story

Yahoo Finance • 7 months ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin d... Full story